Skin toxicity and quality of life in patients with metastatic colorectal cancer during first-line panitumumab plus FOLFIRI treatment in a single-arm phase II study

Table 7 Change in EQ-5D health state index and EQ-5D overall health rating by severity of skin toxicity

	Least-squares adjusted^a mean (95% CI)
	WT KRAS(n = 76)^b	MT KRAS(n = 54)^b	Overall (n = 137)^b
EQ-5D health state index
Worst ST grade 0/1	0.03 (-0.10, 0.15)	0.01(-0.12, 0.14)	0.01 (-0.08, 0.09)
Worst ST grade 2+	0.04 (-0.01, 0.09)	-0.02 (-0.11, 0.06)	0.00 (-0.05, 0.04)
Difference	-0.01 (-0.14, 0.12)	0.03 (-0.12, 0.19)	0.01 (-0.09, 0.10)
EQ-5D overall health rating
Worst ST grade 0/1	-2.4 (-19.1, 14.4)	-3.5 (-12.2, 5.2)	-3.4 (-10.9, 4.2)
Worst ST grade 2+	4.2 (-2.5, 10.9)	-6.1 (-12.0,-0.2)	-1.8 (-5.9, 2.2)
Difference	-6.6 (-24.6, 11.5)	2.6 (-8.0, 13.2)	-1.5 (-10.1, 7.1)

Data are presented as least-squares adjusted mean (95% CI) change in score from baseline through disease progression.
^aMixed effect model including fixed effects of time, skin toxicity, baseline EQ-5D score, and the interaction between time and skin toxicity (ST). Interaction of ST with baseline EQ-5D score with P < 0.1 was also included in the final model, as were random effects for intercept and time; ^bTotal ⁿ shown; actual n number varies for each ST subgroup and scale.

ISSN: 1471-2407